Shares Of Biotech Firm Intellia Therapeutics Soar In Debut
Details
- Publish Date:
- May 7, 2016
- Author(s):
-
- Kosman, Josh
- Source:
- New York Post
- Related Person(s):
- Related Organization(s):
Summary
It’s a brave new world for biotech.
Shares of Intellia Therapeutics — a company that has the potential to “edit” defective genes — soared 23 percent in its trading debut on Friday.
The Cambridge, Mass.-based firm, which sold 6 million shares at $18 apiece, closed at $22.10.
…
“What’s amazing about Crispr is that it is cheap and easy,” said Hank Greely, the director for Stanford’s Law and Biosciences Center.
Read More